On this page you will find the key publications on COVID-19 and psoriasis selected by IPC's Chief Medical Officer.
may 2020 Teledermatologic monitoring for chronic cutaneous autoimmune diseases with smartworking during Covid-19 emergency in a tertiary center in Italy. [published online ahead of print, 2020 May 26]. Brunasso AMG, Massone C. 2020;e13495. doi:10.1111/dth.13695. Chilblain-like lesions: a case series of 41 patients during the COVID-19 pandemic. López-Robles J, de la Hera I, Pardo J, Martínez J, Cutillas-Marco E. Clin Exp Dermatol. 2020 May 5. doi: 10.1111/ced.14275. [Epub ahead of print] Performing dermoscopy in the COVID-19 pandemic. Goldust M, Zalaudek I, Gupta A, Lallas A, Rudnicka L, Navarini AA. Dermatol Ther. 2020 May 5:e13506. doi: 10.1111/dth.13506. [Epub ahead of print] Inpatient Teledermatology During the COVID-19 Pandemic. Rismiller K, Cartron AM, Trinidad JCL. J Dermatolog Treat. 2020 May 4:1-9. doi: 10.1080/09546634.2020.1762843. [Epub ahead of print] Leveraging Technology for Remote Learning in the Era of COVID-19 and Social Distancing: Tips and Resources for Pathology Educators and Trainees. Mukhopadhyay S, Booth AL, Calkins SM, Doxtader EE, Fine SW, Gardner JM, Gonzalez RS, Mirza KM, Jiang XS. Arch Pathol Lab Med. 2020 May 4. doi: 10.5858/arpa.2020-0201-ED. [Epub ahead of print] The risk of respiratory tract infections and symptoms in psoriasis patients treated with IL-17-pathway inhibiting biologics: A metaestimate of pivotal trials relevant to decision-making during the COVID-19 pandemic. Wan MT, Shin DB, Winthrop KL, Gelfand JM. Journal of the American Academy of Dermatology. 2020. doi: https://doi.org/10.1016/j.jaad.2020.05.035. Practice guidelines for teledermatology in Australia. Abbott LM, Miller R, Janda M, Bennett H, Taylor M, Arnold C, Shumack S, Soyer HP, Caffery LJ. Australas. J Dermatol. 2020 May 3. doi: 10.1111/ajd.13301. [Epub ahead of print] The Virologic and Immunologic Effects of Cyclosporine as an Adjunct to Antiretroviral Therapy in Patients Treated during Acute and Early HIV-1 Infection. Martin Markowitz, Florin Vaida, C. Bradley Hare, Daniel Boden, Hiroshi Mohri, Frederick M. Hecht, Robert C. Kalayjian, Ann Conrad, Donna Mildvan, Judith Aberg, Christine Hogan, J. Michael Kilby, Henry H. Balfour, Jr, Kim Schafer, Douglas Richman, Susan Little. The Journal of Infectious Diseases, Volume 201, Issue 9, 1 May 2010, Pages 1298–1302, https://doi.org/10.1086/651664 april 2020 Covid-19 in Immune-Mediated Inflammatory Diseases — Case Series from New York. A. Chen, R. Castillo, S. Adhikari, D. Hudesma. Letter to the editor.NEJM. April 29, 2020. DOI: 10.1056/NEJMc2009567 Classification of the cutaneous manifestations of COVID‐19: a rapid prospective nationwide consensus study in Spain with 375 cases. C. Galván Casas A. Català G. Carretero Hernández P. Rodríguez‐Jiménez D. Fernández Nieto A. Rodríguez‐Villa Lario I. Navarro Fernández R. Ruiz‐Villaverde D. Falkenhain M. Llamas Velasco J. García‐Gavín O. Baniandrés C. González‐Cruz V. Morillas‐Lahuerta X. Cubiró I. Figueras Nart G. Selda‐Enriquez J. Romaní X. Fustà‐Novell A. Melian‐Olivera M. Roncero Riesco P. Burgos‐Blasco J. Sola Ortigosa M. Feito Rodriguez I. García‐Dova. First published:29 April 2020 BJD Dermatologists and SARS-CoV-2: The impact of the pandemic on daily practice. Gisondi P, Piaserico S, Conti A, Naldi L. J Eur Acad Dermatol Venereol.2020 Apr 22. doi: 10.1111/jdv.16515. [Epub ahead of print] Review. Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biological treatment and renal transplanted recipients in maintenance immunosuppressive treatment. Gisondi P, Zaza G, Del Giglio M, Rossi M, Iacono V, Girolomoni G, R. Journal of the American Academy of Dermatology (2020), DOI: https://doi.org/10.1016/ j.jaad.2020.04.085. Dermatologists and SARS-CoV-2: The impact of the pandemic on daily practice. Gisondi P, Piaserico S, Conti A, Naldi L. J Eur Acad Dermatol Venereol. 2020 Apr 22. doi: 10.1111/jdv.16515. [Epub ahead of print] Review. Successful Guselkumab treatment in a psoriatic patient affected with Cornelia de Lange Syndrome, and prosecution during the COVID-19 pandemic. Mugheddu C, Dell'Antonia M, Sanna S, Agosta D, Atzori L, Rongioletti F. Dermatol Ther. 2020 Apr 18. doi: 10.1111/dth.13433. [Epub ahead of print] Successful Guselkumab treatment in a psoriatic patient affected with Cornelia de Lange Syndrome, and prosecution during the COVID-19 pandemic. Mugheddu C, Dell'Antonia M, Sanna S, Agosta D, Atzori L, Rongioletti F. Dermatol Ther. 2020 Apr 18. doi: 10.1111/dth.13433. [Epub ahead of print] COVID-19: risk for cytokine targeting in chronic inflammatory diseases? Schett, G., Sticherling, M. & Neurath, M.F. COVID-19: risk for cytokine targeting in chronic inflammatory diseases?. Nat Rev Immunol (2020). https://doi.org/10.1038/s41577-020-0312-7 Journal articles on coronavirus with relevance for skin diseases and dermatology | Centre of Evidence Based Dermatology (CEBD) Coronavirus Resource for Dermatology https://www.nottingham.ac.uk/research/groups/cebd/resources/coronavirus-resource/journal-articles.aspx [visited April 20, 2020] march 2020 Cutaneous manifestations in COVID‐19: a first perspective. S. Recalcati. JEADV (26 March 2020) https://doi.org/10.1111/jdv.16387 Skin manifestations are emerging in the coronavirus pandemic. M. Alexander Otto. Article from website visited April 3, 2020 COVID-19: combining antiviral and anti-inflammatory treatments. Stebbing J, Phelan A, Griffin I, Tucker C, Oechsie O, Smith D, Richardson P. Lancet Infect Dis. 2020 Apr;20(4):400-402. doi: 10.1016/S1473-3099(20)30132-8. Epub 2020 Feb 27. Baricitinib for COVID-19: a suitable treatment? Favalli EG, Biggioggero M, Maioli G, Caporali R. Lancet Infect Dis. 2020 Apr 3. pii: S1473-3099(20)30262-0. doi: 10.1016/S1473-3099(20)30262-0. [Epub ahead of print] Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. Cantini F, Niccoli L, Matarrese D, Nicastri E, Stobbione P, Goletti D. [published online ahead of print, 2020 Apr 22]. J Infect. 2020;S0163-4453(20)30228-0. doi:10.1016/j.jinf.2020.04.017 Managing Cutaneous Immune-Mediated Diseases During the COVID-19 Pandemic. Torres T, Puig L. Am J Clin Dermatol. 2020 Apr 10. doi: 10.1007/s40257-020-00514-2. [Epub ahead of print] One more paper towel, longer protection. Yu N, Wu L, Su J, Huang K, Zhao S, Chen X. J Am Acad Dermatol. 2020 Apr 1. pii: S0190-9622(20)30486-2. doi: 10.1016/j.jaad.2020.03.064. [Epub ahead of print] COVID-19 and Immunomodulator / Immunosuppressant Use in Dermatology. Price KN, Frew JW, Hsiao JL, Shi VY. J Am Acad Dermatol. 2020 May;82(5):e173-e175. doi: 10.1016/j.jaad.2020.03.046. Epub 2020 Mar 26. february 2020 Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Richardson P, Griffin I, Tucker C, Smith D, Oechsie O, Phelan A, Stebbing J Lancet. 2020 Feb 15;395(10223):e30-e31. doi: 10.1016/S0140-6736(20)30304-4. Epub 2020 Feb 4.
may 2020
Teledermatologic monitoring for chronic cutaneous autoimmune diseases with smartworking during Covid-19 emergency in a tertiary center in Italy. [published online ahead of print, 2020 May 26]. Brunasso AMG, Massone C. 2020;e13495. doi:10.1111/dth.13695.
Chilblain-like lesions: a case series of 41 patients during the COVID-19 pandemic. López-Robles J, de la Hera I, Pardo J, Martínez J, Cutillas-Marco E. Clin Exp Dermatol. 2020 May 5. doi: 10.1111/ced.14275. [Epub ahead of print]
Performing dermoscopy in the COVID-19 pandemic. Goldust M, Zalaudek I, Gupta A, Lallas A, Rudnicka L, Navarini AA. Dermatol Ther. 2020 May 5:e13506. doi: 10.1111/dth.13506. [Epub ahead of print] Inpatient Teledermatology During the COVID-19 Pandemic. Rismiller K, Cartron AM, Trinidad JCL. J Dermatolog Treat. 2020 May 4:1-9. doi: 10.1080/09546634.2020.1762843. [Epub ahead of print] Leveraging Technology for Remote Learning in the Era of COVID-19 and Social Distancing: Tips and Resources for Pathology Educators and Trainees. Mukhopadhyay S, Booth AL, Calkins SM, Doxtader EE, Fine SW, Gardner JM, Gonzalez RS, Mirza KM, Jiang XS. Arch Pathol Lab Med. 2020 May 4. doi: 10.5858/arpa.2020-0201-ED. [Epub ahead of print]
The risk of respiratory tract infections and symptoms in psoriasis patients treated with IL-17-pathway inhibiting biologics: A metaestimate of pivotal trials relevant to decision-making during the COVID-19 pandemic. Wan MT, Shin DB, Winthrop KL, Gelfand JM. Journal of the American Academy of Dermatology. 2020. doi: https://doi.org/10.1016/j.jaad.2020.05.035.
Practice guidelines for teledermatology in Australia. Abbott LM, Miller R, Janda M, Bennett H, Taylor M, Arnold C, Shumack S, Soyer HP, Caffery LJ. Australas. J Dermatol. 2020 May 3. doi: 10.1111/ajd.13301. [Epub ahead of print]
The Virologic and Immunologic Effects of Cyclosporine as an Adjunct to Antiretroviral Therapy in Patients Treated during Acute and Early HIV-1 Infection. Martin Markowitz, Florin Vaida, C. Bradley Hare, Daniel Boden, Hiroshi Mohri, Frederick M. Hecht, Robert C. Kalayjian, Ann Conrad, Donna Mildvan, Judith Aberg, Christine Hogan, J. Michael Kilby, Henry H. Balfour, Jr, Kim Schafer, Douglas Richman, Susan Little. The Journal of Infectious Diseases, Volume 201, Issue 9, 1 May 2010, Pages 1298–1302, https://doi.org/10.1086/651664
april 2020 Covid-19 in Immune-Mediated Inflammatory Diseases — Case Series from New York. A. Chen, R. Castillo, S. Adhikari, D. Hudesma. Letter to the editor.NEJM. April 29, 2020. DOI: 10.1056/NEJMc2009567
Classification of the cutaneous manifestations of COVID‐19: a rapid prospective nationwide consensus study in Spain with 375 cases. C. Galván Casas A. Català G. Carretero Hernández P. Rodríguez‐Jiménez D. Fernández Nieto A. Rodríguez‐Villa Lario I. Navarro Fernández R. Ruiz‐Villaverde D. Falkenhain M. Llamas Velasco J. García‐Gavín O. Baniandrés C. González‐Cruz V. Morillas‐Lahuerta X. Cubiró I. Figueras Nart G. Selda‐Enriquez J. Romaní X. Fustà‐Novell A. Melian‐Olivera M. Roncero Riesco P. Burgos‐Blasco J. Sola Ortigosa M. Feito Rodriguez I. García‐Dova. First published:29 April 2020 BJD
Dermatologists and SARS-CoV-2: The impact of the pandemic on daily practice. Gisondi P, Piaserico S, Conti A, Naldi L. J Eur Acad Dermatol Venereol.2020 Apr 22. doi: 10.1111/jdv.16515. [Epub ahead of print] Review.
Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biological treatment and renal transplanted recipients in maintenance immunosuppressive treatment. Gisondi P, Zaza G, Del Giglio M, Rossi M, Iacono V, Girolomoni G, R. Journal of the American Academy of Dermatology (2020), DOI: https://doi.org/10.1016/ j.jaad.2020.04.085.
Dermatologists and SARS-CoV-2: The impact of the pandemic on daily practice. Gisondi P, Piaserico S, Conti A, Naldi L. J Eur Acad Dermatol Venereol. 2020 Apr 22. doi: 10.1111/jdv.16515. [Epub ahead of print] Review.
Successful Guselkumab treatment in a psoriatic patient affected with Cornelia de Lange Syndrome, and prosecution during the COVID-19 pandemic. Mugheddu C, Dell'Antonia M, Sanna S, Agosta D, Atzori L, Rongioletti F. Dermatol Ther. 2020 Apr 18. doi: 10.1111/dth.13433. [Epub ahead of print] Successful Guselkumab treatment in a psoriatic patient affected with Cornelia de Lange Syndrome, and prosecution during the COVID-19 pandemic. Mugheddu C, Dell'Antonia M, Sanna S, Agosta D, Atzori L, Rongioletti F. Dermatol Ther. 2020 Apr 18. doi: 10.1111/dth.13433. [Epub ahead of print]
COVID-19: risk for cytokine targeting in chronic inflammatory diseases? Schett, G., Sticherling, M. & Neurath, M.F. COVID-19: risk for cytokine targeting in chronic inflammatory diseases?. Nat Rev Immunol (2020). https://doi.org/10.1038/s41577-020-0312-7
Journal articles on coronavirus with relevance for skin diseases and dermatology | Centre of Evidence Based Dermatology (CEBD) Coronavirus Resource for Dermatology https://www.nottingham.ac.uk/research/groups/cebd/resources/coronavirus-resource/journal-articles.aspx [visited April 20, 2020]
march 2020
Skin manifestations are emerging in the coronavirus pandemic. M. Alexander Otto. Article from website visited April 3, 2020
One more paper towel, longer protection. Yu N, Wu L, Su J, Huang K, Zhao S, Chen X. J Am Acad Dermatol. 2020 Apr 1. pii: S0190-9622(20)30486-2. doi: 10.1016/j.jaad.2020.03.064. [Epub ahead of print]
COVID-19 and Immunomodulator / Immunosuppressant Use in Dermatology. Price KN, Frew JW, Hsiao JL, Shi VY. J Am Acad Dermatol. 2020 May;82(5):e173-e175. doi: 10.1016/j.jaad.2020.03.046. Epub 2020 Mar 26.
february 2020
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Richardson P, Griffin I, Tucker C, Smith D, Oechsie O, Phelan A, Stebbing J Lancet. 2020 Feb 15;395(10223):e30-e31. doi: 10.1016/S0140-6736(20)30304-4. Epub 2020 Feb 4.
Return to resource center
EXPert opinions Commentaries on select publications learn more
recent publications on COVID-19 & PSORIASIS National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1. Related Articles National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1. J Am Acad Dermatol. 2020 Sep 03;: Authors: Gelfand JM, Armstrong AW, Bell S, Anesi GL, Blauvelt A, Calabrese C, Dommasch ED, Feldman SR, Gladman D, Kircik L, Lebwohl M, Lo RV, Martin G, Merola JF, Scher JU, Schwartzman S, Treat JR, Van Voorhees AS, Ellebrecht CT, Fenner J, Ocon A, Syed MN, Weinstein EJ, Smith J, Gondo G, Heydon S, Koons S, Ritchlin CT Abstract OBJECTIVE: To provide guidance about management of psoriatic disease during the COVID-19 pandemic. STUDY DESIGN: A task force (TF) of 18 physician voting members with expertise in dermatology, rheumatology, epidemiology, infectious diseases, and critical care was convened. The TF was supplemented by non-voting members which included fellows and National Psoriasis Foundation (NPF) staff. Clinical questions relevant to the psoriatic disease community were informed by questions received by the NPF. A Delphi process was conducted. RESULTS: The TF approved 22 guidance statements. The average of the votes was within the category of agreement for all statements. All guidance statements proposed were recommended, 9 with high consensus, 13 with moderate consensus. LIMITATIONS: The evidence behind many guidance statements is limited in quality. CONCLUSION: These statements provide guidance for the management of patients with psoriatic disease on topics ranging from how the disease and its treatments impact COVID-19 risk and outcome, how medical care can be optimized during the pandemic, what patients should do to lower their risk of getting infected with SARS-CoV-2 and what they should do if they develop COVID-19. The guidance is intended to be a living document that will be updated by the TF as data emerge. PMID: 32891785 [PubMed - as supplied by publisher] COVID-19 and systemic therapies in psoriasis: experience of a tertiary hospital in Madrid. Related Articles COVID-19 and systemic therapies in psoriasis: experience of a tertiary hospital in Madrid. Int J Dermatol. 2020 Sep 04;: Authors: Fulgencio-Barbarin J, Puerta-Peña M, Ortiz-Romero P, García-Donoso C, Rivera-Diaz R PMID: 32886364 [PubMed - as supplied by publisher] Nonadherence to Treatment and Patient-Reported Outcomes of Psoriasis During the COVID-19 Epidemic: A Web-Based Survey. Related Articles Nonadherence to Treatment and Patient-Reported Outcomes of Psoriasis During the COVID-19 Epidemic: A Web-Based Survey. Patient Prefer Adherence. 2020;14:1403-1409 Authors: Wang Q, Luo Y, Lv C, Zheng X, Zhu W, Chen X, Shen M, Kuang Y Abstract Purpose: The COVID-19 epidemic has caused difficulties in continuous treatment for patients with chronic diseases and resulted in nonadherence to treatment and adverse health outcomes. This study aimed to investigate the associations of nonadherence to treatment with patient-reported outcomes of psoriasis during the COVID-2019 epidemic. Methods: A cross-sectional study among Chinese patients with psoriasis was conducted through a web-based questionnaire survey during 25 Feb 2020 and 6 Mar 2020. Demographic and clinical data, nonadherence to treatment, and patient-reported outcomes were collected. The outcomes included deterioration of the disease condition, perceived stress, and symptoms of anxiety and depression. Logistic regression was used to investigate the associations. Results: A total of 926 questionnaires were collected. A total of 634 (68.5%) reported nonadherence to treatment, and worse adherence was found among patients receiving systemic treatment (adjusted odds ratio [AOR]: 2.67; 95% CI: 1.40-5.10) and topical treatment (AOR: 4.51; 95% CI: 2.66-7.65) compared to biological treatment. Nonadherence to treatment (less than two weeks and more than two weeks) was significantly associated with deterioration of psoriasis (aOR: 2.83 to 5.25), perceived stress (AOR: 1.86 to 1.57), and symptoms of anxiety (AOR: 1.42 to 1.57) and depression (AORs: 1.78). Subgroup analysis by treatment showed consistent results in general. Conclusion: Nonadherence to treatment was associated with the aggravation of psoriasis conditions, perceived stress, and symptoms of anxiety and depression. PMID: 32884243 [PubMed] View all publications from PubMed
recent publications on COVID-19 & PSORIASIS
National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1.
J Am Acad Dermatol. 2020 Sep 03;:
Authors: Gelfand JM, Armstrong AW, Bell S, Anesi GL, Blauvelt A, Calabrese C, Dommasch ED, Feldman SR, Gladman D, Kircik L, Lebwohl M, Lo RV, Martin G, Merola JF, Scher JU, Schwartzman S, Treat JR, Van Voorhees AS, Ellebrecht CT, Fenner J, Ocon A, Syed MN, Weinstein EJ, Smith J, Gondo G, Heydon S, Koons S, Ritchlin CT
Abstract OBJECTIVE: To provide guidance about management of psoriatic disease during the COVID-19 pandemic. STUDY DESIGN: A task force (TF) of 18 physician voting members with expertise in dermatology, rheumatology, epidemiology, infectious diseases, and critical care was convened. The TF was supplemented by non-voting members which included fellows and National Psoriasis Foundation (NPF) staff. Clinical questions relevant to the psoriatic disease community were informed by questions received by the NPF. A Delphi process was conducted. RESULTS: The TF approved 22 guidance statements. The average of the votes was within the category of agreement for all statements. All guidance statements proposed were recommended, 9 with high consensus, 13 with moderate consensus. LIMITATIONS: The evidence behind many guidance statements is limited in quality. CONCLUSION: These statements provide guidance for the management of patients with psoriatic disease on topics ranging from how the disease and its treatments impact COVID-19 risk and outcome, how medical care can be optimized during the pandemic, what patients should do to lower their risk of getting infected with SARS-CoV-2 and what they should do if they develop COVID-19. The guidance is intended to be a living document that will be updated by the TF as data emerge.
PMID: 32891785 [PubMed - as supplied by publisher]
COVID-19 and systemic therapies in psoriasis: experience of a tertiary hospital in Madrid.
Int J Dermatol. 2020 Sep 04;:
Authors: Fulgencio-Barbarin J, Puerta-Peña M, Ortiz-Romero P, García-Donoso C, Rivera-Diaz R
PMID: 32886364 [PubMed - as supplied by publisher]
Nonadherence to Treatment and Patient-Reported Outcomes of Psoriasis During the COVID-19 Epidemic: A Web-Based Survey.
Patient Prefer Adherence. 2020;14:1403-1409
Authors: Wang Q, Luo Y, Lv C, Zheng X, Zhu W, Chen X, Shen M, Kuang Y
Abstract Purpose: The COVID-19 epidemic has caused difficulties in continuous treatment for patients with chronic diseases and resulted in nonadherence to treatment and adverse health outcomes. This study aimed to investigate the associations of nonadherence to treatment with patient-reported outcomes of psoriasis during the COVID-2019 epidemic. Methods: A cross-sectional study among Chinese patients with psoriasis was conducted through a web-based questionnaire survey during 25 Feb 2020 and 6 Mar 2020. Demographic and clinical data, nonadherence to treatment, and patient-reported outcomes were collected. The outcomes included deterioration of the disease condition, perceived stress, and symptoms of anxiety and depression. Logistic regression was used to investigate the associations. Results: A total of 926 questionnaires were collected. A total of 634 (68.5%) reported nonadherence to treatment, and worse adherence was found among patients receiving systemic treatment (adjusted odds ratio [AOR]: 2.67; 95% CI: 1.40-5.10) and topical treatment (AOR: 4.51; 95% CI: 2.66-7.65) compared to biological treatment. Nonadherence to treatment (less than two weeks and more than two weeks) was significantly associated with deterioration of psoriasis (aOR: 2.83 to 5.25), perceived stress (AOR: 1.86 to 1.57), and symptoms of anxiety (AOR: 1.42 to 1.57) and depression (AORs: 1.78). Subgroup analysis by treatment showed consistent results in general. Conclusion: Nonadherence to treatment was associated with the aggravation of psoriasis conditions, perceived stress, and symptoms of anxiety and depression.
PMID: 32884243 [PubMed]
View all publications from PubMed